Monitor for definitive contract award from DARPA, which would provide non-dilutive funding and government validation. The stock may see continued momentum on this government endorsement, but the lack of a binding award means the catalyst is incomplete, watch for follow-up 8-K on contract terms.
NRXP drugs
NRXP drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 22 $4.48entry
- T+1 · 4mo ago −8.26%α −7.02% · $4.11
- T+5 · 4mo ago −27.90%α −25.50% · $3.23
- T+20 · 3mo ago −25.67%α −28.57% · $3.33
- T+60 · 5w ago −39.51%α −42.77% · $2.71
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
NRX Pharmaceuticals' subsidiary NRX Defense Systems received a letter from DARPA indicating its SPARC-TMS clinical trial proposal was selected for negotiation of a potential award. The Phase 2/3 trial combines robotic-enabled TMS with NRX-101 (which has FDA Breakthrough Therapy Designation) for depression remission. This is a non-binding selection, no award has been made and definitive terms remain subject to negotiation, but it represents a significant validation of the company's technology platform by a major government agency.
Key Facts
- NRX Defense Systems (NRXD) received a letter from DARPA selecting its SPARC-TMS proposal for negotiation of a potential award.
- The SPARC-TMS trial is a Phase 2/3 trial combining robotic-enabled Transcranial Magnetic Stimulation with NRX-101 (D-cycloserine/lurasidone) for depression remission.
- NRX-101 previously received FDA Breakthrough Therapy Designation.
- The trial protocol is FDA-approved and posted on clinicaltrials.gov (NCT07227103).
- The study is planned at Harvard McLean Hospital, HOPE Therapeutics clinics, and military treatment facilities including Walter Reed.
- The selection does not constitute a notice of award or commitment by DARPA; final award is subject to successful negotiation of definitive terms.
Financial Impact
No financial terms disclosed. DARPA contract value is TBD and subject to negotiation.
Risk Factors
- No binding award yet, DARPA may not finalize terms or may cancel negotiations.
- NRX Pharmaceuticals is a small-cap biotech with no disclosed revenue from this program; the stock may be volatile on binary government contract news.
- The Phase 2/3 trial carries clinical risk, efficacy or safety issues could derail the program.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-024037 |
| Document: 0001437749-26-024037-index-headers.html | 0001437749-26-024037 |
| Document: 0001437749-26-024037-index.html | 0001437749-26-024037 |
| Document: 0001437749-26-024037.txt | 0001437749-26-024037 |
Track record
22 reports on NRXP
8 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 10 of 12 went positive at some point.
Filters
- Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
- Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
- Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
- Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
- Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
- Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers